TY - JOUR
T1 - Differential effects of bryostatin 1 on human non-hodgkin's B-lymphoma cell lines
AU - Mohammad, R. M.
AU - Al-Katib, A.
AU - Pettit, George
AU - Sensenbrenner, L. L.
N1 - Funding Information:
Acknowledgements--This publication was made possible by grant No. R29 CA50715-01A1 from the U.S. National Cancer Institute. The ASU-CRI component received support from the Fannie E. Rippel Foundation, The Robert B. Dalton Endowment Fund, outstanding Investigator Grant CA 44344-01A1 from the U.S. National Cancer Institute, DHHS, and the Arizona Disease Control Research Commission.
PY - 1993/1
Y1 - 1993/1
N2 - Bryostatin 1 (Bryo1), a macrocyclic lactone and a protein kinase C activator, is extracted and purified from the marine bryozoan Bugula neritina. In this study we describe its effect on morphology, surface immunophenotype, acid phosphatase (AcP), tartrate-resistant acid phosphatase (TRAP), proliferation and cell cycle of non-Hodgkin's B-lymphoma cell lines representing four differentiation stages. Except for the WSU-BL, a high-grade SCNCL, all other cell lines showed obvious changes in their morphology when treated with 200 nM Bryol. Phenotypically, a dramatic decrease of CD10 and induction of CD11c and BL7 on some cell lines consistent with further B-cell differentiation was seen. The lines in control cultures showed variable expression of AcP and TRAP. Following treatment with Bryol, there was a general increase in AcP expression except in WSU-BL line. WSU-FSCCL and WSU-DLCL were TRAP-negative but became TRAP-positive when treated with Bryol. Cell growth and cycle analysis during treatment of different cell lines revealed evidence of strong, moderate, or no growth inhibition by Bryol compared with control cultures. Our results indicate that Bryol shows differentiation effects on low-grade FSCCL, intermediate-grade FLCL and high-grade DLCL, and stimulatory or no effect on high-grade SCNCL. Since Bryo1 does not have tumor-promoting activity, it has a potential therapeutic role as a B-cell differentiating agent.
AB - Bryostatin 1 (Bryo1), a macrocyclic lactone and a protein kinase C activator, is extracted and purified from the marine bryozoan Bugula neritina. In this study we describe its effect on morphology, surface immunophenotype, acid phosphatase (AcP), tartrate-resistant acid phosphatase (TRAP), proliferation and cell cycle of non-Hodgkin's B-lymphoma cell lines representing four differentiation stages. Except for the WSU-BL, a high-grade SCNCL, all other cell lines showed obvious changes in their morphology when treated with 200 nM Bryol. Phenotypically, a dramatic decrease of CD10 and induction of CD11c and BL7 on some cell lines consistent with further B-cell differentiation was seen. The lines in control cultures showed variable expression of AcP and TRAP. Following treatment with Bryol, there was a general increase in AcP expression except in WSU-BL line. WSU-FSCCL and WSU-DLCL were TRAP-negative but became TRAP-positive when treated with Bryol. Cell growth and cycle analysis during treatment of different cell lines revealed evidence of strong, moderate, or no growth inhibition by Bryol compared with control cultures. Our results indicate that Bryol shows differentiation effects on low-grade FSCCL, intermediate-grade FLCL and high-grade DLCL, and stimulatory or no effect on high-grade SCNCL. Since Bryo1 does not have tumor-promoting activity, it has a potential therapeutic role as a B-cell differentiating agent.
KW - B-cell lymphoma
KW - bryostatin 1
KW - differentiation
KW - protein kinase C
UR - http://www.scopus.com/inward/record.url?scp=0027474602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027474602&partnerID=8YFLogxK
U2 - 10.1016/0145-2126(93)90134-7
DO - 10.1016/0145-2126(93)90134-7
M3 - Article
C2 - 8429674
AN - SCOPUS:0027474602
SN - 0145-2126
VL - 17
SP - 1
EP - 8
JO - Leukemia Research
JF - Leukemia Research
IS - 1
ER -